Is TRxADE HEALTH, Inc. overvalued or undervalued?

As of 26 March 2025, the valuation grade for TRxADE HEALTH, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.12 and an EV to Sales ratio of 11.15, which suggests that the market is pricing it excessively relative to its sales performance. Additionally, the company has a negative ROCE of -15.44% and a negative ROE of -17.32%, further underscoring its financial struggles.
In comparison to peers, TRxADE HEALTH, Inc. is underperforming against companies like SilverSun Technologies, Inc., which has a P/E ratio of 318.49, and Ashford, Inc., with an EV to EBITDA of 1.88. The stark contrast in these ratios highlights the challenges TRxADE faces in attracting investor confidence. Furthermore, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -85.12% compared to the index's 2.44%. Overall, TRxADE HEALTH, Inc. is deemed overvalued in its current state.